H.C. Wainwright upgraded Fulcrum Therapeutics (FULC) to Buy from Neutral with a price target of $12, up from $4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $15 from $12 at Oppenheimer
- Fulcrum Therapeutics Announces Promising Phase 1b Trial Results
- Fulcrum Therapeutics’ pociredir shows efficacy in sickle cell disease
- Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)
- Fulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs